Enovis Stock Hits 52-Week Low at $21 as Evercore Upholds $40 Target
Enovis shares plunged 50% over the past year to a 52-week low of $21.00 on January 29, 2026 following a Q4 revenue shortfall of about 3%. Evercore ISI reiterated an Outperform rating with a $40 target, highlighting an 11% EPS beat and forecasting FY26 free cash flow conversion above 25%.
1. Performance Slump and 52-Week Low
Enovis shares tumbled 50% over the past year, reaching a 52-week low of $21.00 on January 29, 2026 after facing macroeconomic headwinds throughout 2025.
2. Evercore ISI Rating Update
On January 12, Evercore ISI reiterated its Outperform rating on Enovis with a $40 price target, highlighting a roughly 3% Q4 revenue shortfall offset by an implied 11% EPS beat and forecasting FY26 free cash flow conversion above 25%.
3. BTIG Coverage Initiation
On January 6, BTIG initiated coverage of Enovis with a Buy rating and a $41 target, citing the company’s multi-segment orthopedic strategy and potential to outperform end markets despite concerns over scale, tariffs, and cash flow.